OncoMatch/Clinical Trials/NCT06158386
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Is NCT06158386 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Chidamide combined with Linperlisib for follicular lymphoma.
Treatment: Chidamide combined with Linperlisib — To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: anti-CD20 monoclonal antibody — first-line
at least one of the first-line treatments includes anti-CD20 monoclonal antibody (anti-CD20 monoclonal antibody monotherapy or combined chemotherapy)
Cannot have received: PI3K inhibitor
Exception: disease has progressed during the treatment period (within 6 months after the last use)
Any PI3K inhibitor has been used before and the disease has progressed during the treatment period (within 6 months after the last use)
Cannot have received: systemic anti-tumor therapy
Received systemic anti-tumor therapy or radiotherapy within 4 weeks before enrollment
Cannot have received: radiotherapy
Received systemic anti-tumor therapy or radiotherapy within 4 weeks before enrollment
Cannot have received: hematopoietic stem cell transplantation
Exception: within 3 months before enrollment
The patients received the transplantation of somatic hematopoietic stem cells within 3 months before enrollment
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: within 6 months before drug administration or any active graft-versus-host disease
Patients received allogeneic hematopoietic stem cell transplantation or had any active graft-versus-host disease within 6 months before drug administration
Lab requirements
Blood counts
neutrophils < 1.5× 10^9/L, HB < 80 g/L, PLT < 75×10^9 /L
Kidney function
glomerular filtration rate (eGFR) < 30 ml/min
Liver function
serum total bilirubin > 1.5 x ULN or serum ALT and AST > 2.5x ULN; with liver infiltration by lymphoma, AST and ALT > 5x ULN
Cardiac function
all kinds of clinically significant abnormal rhythm or conduction; Hereditary QT interval syndrome or QTcF>480 msec or taking drugs that may cause QT interval delay or torsade de pointes; acute myocardial infarction, unstable angina, and coronary artery bypass grafting in the first 6 months; NYHA grade 3 or above; LVEF <40%; uncontrolled blood pressure (Systolic > 160 mmHg or diastolic > 100 mmHg)
Impaired bone marrow function: neutrophils < 1.5× 10^9/L, HB < 80 g/L, PLT < 75×10^9 /L, Impaired liver function, defined as serum total bilirubin > 1.5 x ULN or serum ALT and AST > 2.5x ULN, Patients with liver infiltration by lymphoma, AST and ALT > 5x ULN, Renal glomerular filtration rate (eGFR) < 30 ml/min. PT INR>1.5ULN or APTT> 1.5 ULN, Serum amylase or lipase > 1ULN. ... all kinds of clinically significant abnormal rhythm or conduction need clinical pre-diagnosis Hereditary QT interval syndrome or QTcF>480 msec or taking drugs that may cause Qt interval delay or torsade de pointes. A variety of clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, and coronary artery bypass grafting in the first 6 months of the group, with New York's cardiology (NYHA) classification of grade 3 or above. Left ventricular ejection fraction (LVEF )<40%, or uncontrolled blood pressure controlled by drugs (Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mgHg).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06158386 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PI3K inhibitor, systemic anti-tumor therapy, radiotherapy disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages